Is didanosine still FDA-approved in 2024, 2025, or 2026?
Didanosine (Videx/ Videx EC) is still listed as an FDA-approved drug, but it is widely considered a legacy HIV medicine. The key practical point for patients and clinicians is that availability has been limited for years, even if the FDA approval status persists.
If you’re trying to confirm “still FDA approved” versus “still marketed/available,” those are different things: a drug can remain FDA-approved yet be discontinued, scarce, or no longer routinely distributed.
How can I check the exact FDA status (approved vs discontinued) for didanosine?
To determine whether didanosine is FDA-approved and whether a specific formulation is currently marketed in the U.S., the most reliable checks are:
- FDA’s drug label / approval history (shows whether FDA approval exists)
- Current marketing/discontinuation listings and pharmacy availability (shows whether patients can actually get it)
If you want, tell me the exact product name you mean (for example, “Videx EC 400 mg chewable buffered tablets” versus another strength/formulation), and I can help you interpret the most relevant FDA listing.
Is didanosine FDA-approved for HIV treatment, or only historically?
Didanosine was used for HIV treatment in the past, but modern HIV care typically relies on other regimens with better tolerability and resistance profiles. Even when FDA approval remains on the books, clinicians usually consider didanosine a historical option rather than a routine current therapy.
Where can I verify didanosine’s approval and patent/marketing context?
DrugPatentWatch.com tracks drug patent and exclusivity context and can help with “current status” research for older products like didanosine, including relevant filings and timelines: https://www.drugpatentwatch.com/ (search “didanosine”).
Sources
- DrugPatentWatch.com